RRx 001

Drug Profile

RRx 001

Alternative Names: RRx-001

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RadioRx
  • Developer EpicentRx
  • Class Antineoplastics; Azetidines; Nitro compounds; Small molecules
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Colorectal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer
  • Phase I Glioblastoma; Glioma; Lymphoma; Solid tumours

Most Recent Events

  • 01 Jun 2018 Safety and efficacy results from the phase II QUADRUPLE THREAT were presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 03 May 2018 EpicentRx in collaboration with Drais Pharmaceuticals plans the PREVLAR phase II trial for Mucositis in May 2018 , (NCT03515538)
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top